The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection
Open accessAbstract
The resistance rates of Helicobacter pylori to amoxicillin and metronidazole therapy are higher in eastern Taiwan as compared to national and worldwide rates. The high resistance rate in this territory justified a search for a better eradication regimen. We conducted an open-labeled, prospective, randomized, and controlled study in a tertiary referral hospital in eastern Taiwan. Between December 2007 and December 2009, a total of 153 Helicobacter pylori-positive, therapy-naïve patients with a positive rapid urease test were recruited for random assignment to two seven-day treatment groups: levofloxacin (500 mg), amoxicillin/clavulanate (875 mg/125 mg), and rabeprazole (20 mg) twice per day (LAcR) or clarithyromicin (500 mg), amoxicillin (1000 mg), and rabeprazole (20 mg) twice per day (CAR). Helicobacter pylori eradication was assessed using the (13)C-urea breath test or rapid urease test performed at least 4 weeks after the end of treatment. After exclusion, 146 patients were enrolled and allocated in the study. The Helicobacter pylori eradication rates analyzed by both intention to treat (78.1% versus 57.5%, P = 0.008) and perprotocol (80.9% versus 61.8%, P = 0.014) were significantly higher for the LAcR group. In conclusion, the seven-day LAcR regimen provided improved Helicobacter pylori eradication efficacy when compared with the standard CAR triple therapy in eastern Taiwan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a comparative study from Eastern Taiwan, the LAcR regimen, comprising levofloxacin, amoxicillin/clavulanate, and rabeprazole, achieved significantly higher eradication and symptom resolution rates than standard clarithromycin-based triple therapy (78.1% vs. 57.5%, p<0.05), underscoring the therapeutic relevance of co-amoxiclav-containing regimens in resistance-tailored treatment strategies [23]”
From Clinical Outcomes and Real-World Effectiveness of Amoxicillin-Clavulanic Acid Across Indian Healthcare Settings: A Retrospective Multicenter Study (2026) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malfertheiner, P., Mégraud, F., O'Morain, C. A., Bazzoli, F., El-Omar, E. M., Graham, D., Hunt, R. H., Rokkas, T., Vakil, N. B., Kuipers, E. J., et al. (2006) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,242
Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China
Wong, B. C., Lam, S. K., Wong, W. M., Chen, J. S., Zheng, T., Feng, R. E., Lai, K. C., Hu, W. H. C., Yuen, S. T., Leung, S. Y., et al. (2004) · JAMA · doi:10.1001/jama.291.2.187 · Cited by 1,436
American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
Chey, W. D., & Wong, B. C. Y. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01393.x · Cited by 1,411
Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
Fock, K. M., Katelaris, P., Sugano, K., et al. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05982.x · Cited by 555
Worldwide H. pylori antibiotic resistance: a systematic review.
Francesco, V. D., Giorgio, F., Hassan, C., et al. (2010) · PubMed · Cited by 480
Ishizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 429
New concepts of resistance in the treatment of Helicobacter pylori infections
Graham, D. Y., & Shiotani, A. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1138 · Cited by 357
Saad, R. J., Schoenfeld, P., Kim, H. M., et al. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00637.x · Cited by 261
Wu, D., Hsu, P., Wu, J., Opekun, A. R., Kuo, C., Wu, I. –., Wang, S. S. W., Chen, A., Hung, W., & Graham, D. Y. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.09.030 · Cited by 242
Self-citationPadol, S., Yuan, Y., Thabane, M. E., Padol, I. T., & Hunt, R. H. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00717.x · Cited by 159
Research works printed but not linked: 4
- 2010, Journal of Gastrointestinal and Liver Diseases, 19, 409
- 1998, Acta Medica Croatica, 52, 209
- 2009, Revista Espanola de Enfermedades Digestivas, 101, 395
- 1999, Alimentary Pharmacology and Therapeutics, Supplement, 13, 27
Cited by
Sorted by citations
Raju, A., Kakar, A., Bhagat, D. K., Behera, S. K., Pathak, R., & Pal, S. (2026) · Cureus · doi:10.7759/cureus.104282
“…and rabeprazole, achieved significantly higher eradication and symptom resolution rates than standard clarithromycin-based triple therapy (78.1% vs. 57.5%, p 0.05), underscoring the therapeutic relevance of co-amoxiclav-containing regimens in resistance-tailored treatment strategies [23].”
Influential
Metadata
- Authors
- Chen, M.-C., Lei, W.-Y., Lin, J.-S., Yi, C.-H., Wu, D.-C., & Hu, C.-T.
- Affiliations
- Luodong Poh-Ai Hospital (TW)
- Tzu Chi Foundation (TW)
- Tzu Chi University (TW)
- Kaohsiung Medical University (TW)
- Corresponding author
- Hu, Chi-Tan
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2014
- Volume
- 2014
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC4066685
- OpenAlex
- W1975241840
- Cited by
- 21
- References
- 36
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2020: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 6
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Helicobacter pylori, triple therapy, levofloxacin, amoxicillin-clavulanic acid, rabeprazole, clarithromycin, amoxicillin, eradication efficacy, antibiotic resistance, 13C-urea breath test, rapid urease test, eastern Taiwan
- MeSH terms
- Amoxicillin, Drug Combinations, Female, Humans, Male, Helicobacter pylori, Helicobacter Infections, Clavulanic Acid, Drug Resistance, Bacterial, Levofloxacin, Rabeprazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
